Navigation Links
China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results
Date:2/28/2011

levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to confirm these statements to actual results, unless required by law.

The forward-looking statements included in this press release are subject to risks, uncertainties and assumptions about our businesses and business environments. These statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual results of our operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People's Republic of China, or PRC; changing legislation or regulatory environments in the PRC; the acceptance by subscribers of the Company's different pricing and payment options; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company's ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, as well as general economic conditions; and other relevant risks detailed in the Company's filings with the Securities and Exchange Commission.

This announcement contains translations of certain Renminbi amounts into U.S. dollars at s
'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ShengdaTech to Present at Rodman & Renshaw Annual China Investment Conference in Shanghai
2. China Cord Blood Corporation Forms Zhejiang Subsidiary
3. China Cord Blood Corporation Announces Results of 2010 Annual General Meeting
4. China Cord Blood Corporation to Announce Third Quarter Fiscal 2011 Financial Results
5. China-Biotics to Report Fiscal Year 2011 Third Quarter Financial Results on February 9
6. China-Biotics, Inc. Provides Preliminary FY2011Third Quarter Revenue
7. Reportlinker Adds Industrial Biotechnology China News 1011
8. Reportlinker Adds Financial Health of Biotechnology and Drugs Industry in India and China
9. China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on February 18, 2011
10. China-Biotics, Inc. to Hold 2010 Annual Meeting of Stockholders on March 9, 2011
11. China Cord Blood Corporation Announces Completion of Warrant Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... FL (PRWEB) , ... June 30, 2015 , ... The ... 7.76% of Cryo-Cell’s currently outstanding common shares (including shares of unvested restricted stock). On ... offer, the last sale price of Cryo-Cell’s shares reported on the OTCBB was $2.29 ...
(Date:6/30/2015)... 2015  Custom Computer Specialists, Inc. ("Custom"), a leading ... silver sponsors of the Primary Care Development Corporation,s ("PCDC") ... lending their support of PCDC,s mission to expand access ... its founding in 1993, PCDC has been a key ... has financed over 100 completed primary care projects, valued ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... 14. She has accepted the position of vice president of instruction at Chippewa ... , “I greatly appreciated the opportunity to lead SIUE during the past ...
(Date:6/29/2015)... NY (PRWEB) , ... June 30, 2015 , ... This ... and Perkin Elmer machines. Featuring 12 distinct peaks, the WAV-8 is the world’s ... machine is in spec deep into the NIR range. Previous spectrophotometer calibration standards, such ...
Breaking Biology Technology:Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3
... BEACH, Calif., Jan. 4, 2011 Genesis Biopharma, Inc. ... company developing targeted cancer therapies, today announced that it ... to which it entered into definitive agreements with accredited ... the Genesis Biopharma common stock for a purchase price ...
... Va., Jan. 3, 2011 BNA Books , a ... Second Edition of ... that provides an in-depth consideration of the entire body of ... (Logo: http://photos.prnewswire.com/prnh/20090529/DC24463LOGO )   ...
... a clinical-stage regenerative medicine company developing novel therapies ... and Drug Administration (FDA) authorized commencement of a ... safety of its lead product, JVS-100, for the ... Stromal-cell Derived Factor 1 (SDF-1), which has been ...
Cached Biology Technology:Genesis Biopharma Raises $845,000 in Private Financings 2New Second Edition of Biotechnology and the Federal Circuit Examines the Court's Decisions on Chemical, Biotechnology, and Pharmaceutical Patent Law Cases 2New Second Edition of Biotechnology and the Federal Circuit Examines the Court's Decisions on Chemical, Biotechnology, and Pharmaceutical Patent Law Cases 3New Second Edition of Biotechnology and the Federal Circuit Examines the Court's Decisions on Chemical, Biotechnology, and Pharmaceutical Patent Law Cases 4Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia 2Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia 3
(Date:6/24/2015)... NEW YORK , June 24, 2015 ... Systems market, over the next six years. It contains ... affect the industry, along with their impact from the ... It also discusses the industry, market, and technology ... expected that the need of concerned authorities to efficiently ...
(Date:6/23/2015)... MINNETONKA, Minn. , June 23, 2015 /PRNewswire/ ... technology company that supports the entire spectrum of ... iMedNet ™ , the company,s ... has been awarded a Silver 2015 Stevie® Award ... the Health Products & Services Website category.  The ...
(Date:6/18/2015)... NEW YORK , June 18, 2015 ... in US$ Million by the following Product Segments, which ... Immunoassay Systems, Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and ... for the US, Canada , ... Asia-Pacific , Latin America ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... Bloomberg School of Public Health has received $28 million ... the David and Lucile Packard Foundation and the William ... Advance Family Planning advocacy initiative within the Bloomberg School,s ... Health. Advance Family Planning aims to increase ...
... PHILADELPHIAResearchers at the Kimmel Cancer Center at Jefferson (KCC) ... have developed potentially game-changing diagnostic and prognostic genetic tests ... distinguish clinically-relevant cancers. The team, led ... of the KCC and the Chair of the ...
... functional body: as embryos develop and grow, they must form ... the embryo. The exact mechanism underlying this fundamental characteristic, called ... EMBL Heidelberg is now one step closer to understanding it. ... a mouse embryo is controlled by how the expression of ...
Cached Biology News:Bloomberg School receives $28 million for family planning advocacy 2Game changing diagnostic & prognostic prostate cancer genetic tests revealed by Jefferson 2Game changing diagnostic & prognostic prostate cancer genetic tests revealed by Jefferson 3Sync to grow 2
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
Biology Products: